AiCuris: Deal of the year
03.06.2013 - Bayer AG’s anti-infectives spin-out AiCuris GmbH and license partner Merck & Co. have been awarded the Allicense 2013 "Breakthrough Alliance Award” for their US$574m agreement in October 2012.
In the running were the five most valuable licensing agreements worldwide as nominated by analysts from Deloitte Recap. An online vote decided the winner. AiCuris CEO Prof. Dr. Helga Rübsamen-Schaeff was given the award at the end of April at the Allicense conference in San Francisco.http://www.european-biotechnology-news.com/people/bio-people/2013-01/helga-ruebsamen.html